Menu Back to Diversity-Equity-and-Inclusion-in-the-Drug-Development-Lifecycle-Meeting


DIA’s Diversity, Equity, and Inclusion in the Drug Development Lifecycle Meeting will lead the way in sharing knowledge and fostering coalitions to build greater diversity, equity, and inclusion in the drug development lifecycle. Moving beyond describing the problems that exist in this space, the meeting will emphasize approaches and solutions in which our field has been investing. The meeting will include interactive and compelling discussions and exercises that will lead to a better understanding of how we can improve as an industry to encourage accountability and sustainability of efforts. An important purpose of the meeting is to advance dialogue among thought leaders from industry, clinical research sites, patient engagement, academia, FDA, and public policy to spur additional ideas to move the field forward.

This program has been developed in collaboration with the Diversity in Life Sciences Community.

Who should attend?

  • Clinical Research
  • Clinical Operations
  • Data transparency/data sharing
  • Diversity, Equity and Inclusion
  • Health Outcomes
  • Medical Affairs and Communication
  • Patient Advocacy
  • Patient Engagement/Patient Support
  • Professional Education, Training and Development
  • Public Policy
  • Research and Development
  • Regulatory Affairs
  • Strategic Planning

Learning objectives

At the conclusion of this activity, participants should be able to:
  • Recognize how to engage and be proactive to the needs of diverse communities to build trust and combat misinformation
  • Identify strategies that work towards efforts of diversity, equity and inclusion with relation to the drug development lifecycle
  • Restate dialogue regarding the importance of genomics in discovery science and early clinical development
  • Apply how to engage Institutional Review Boards (IRBs) and Independent Ethics Committees (IECs) on diversity, equity, and inclusion efforts within clinical trials and throughout the drug development lifecycle
  • Explain the conscious decision making it takes for a company to pursue diversity in clinical trials
  • Evaluate the challenges that impact diversity recruitment, enrollment, and retention in clinical trials
  • Describe FDA efforts to advance the inclusion of minorities and women in clinical trials
  • Identify industry efforts that support clinical trial diversity
  • Explain clinical research site activities that advance clinical trial diversity through community engagement
  • Discuss how to engage and support health equity and access during the post-marketing phase of the drug development lifecycle

Program Committee

  • Monique  Adams, PhD, MS
    Monique Adams, PhD, MS Director, Clinical Innovation Lead
    Janssen, United States
  • Richardae  Araojo, PharmD, MS
    Richardae Araojo, PharmD, MS Associate Commissioner for Minority Health, Director, Office of Minority Health
    FDA, United States
  • Dyan  Bryson, MBA
    Dyan Bryson, MBA Patient Engagement Strategist/Patient Advocate
    Inspired Health Strategies, United States
  • Robert Elliott Fullilove, EdD, MS
    Robert Elliott Fullilove, EdD, MS Associate Dean, Community and Minority Affairs
    Columbia University, United States
  • Diana  Foster, BSN, PhD, MSN
    Diana Foster, BSN, PhD, MSN Vice President, Strategy and Special Projects
    Society for Clinical Research Sites, United States
  • Adaeze  Enekwechi, PhD
    Adaeze Enekwechi, PhD Board Member
    Alliance for Health Policy, United States
  • Charlotte  Jones-Burton, MD, MS
    Charlotte Jones-Burton, MD, MS Vice President
    Otsuka Pharmaceutical, United States
  • Mustafa  Syed, PharmD
    Mustafa Syed, PharmD President, DIA Student Chapter
    St. Johns University, United States
  • Amy  Sitnick, MA
    Amy Sitnick, MA Vice President, Marketing
    Greenphire, United States
Load More

Contact us

Registration Questions?

Send Email

Digital Learning Catalog

DIA Learning: eLearning Soultions